METASTATIC COLORECTAL CANCER

This study aimed to test whether two immunotherapy drugs (tiragolumab and atezolizumab) plus targeted radiation could help people with a specific, hard-to-treat type of advanced colorectal cancer called MSS mCRC. The trial was planned for adults aged 18 and older whose cancer had…

This early-phase study tests a new type of universal CAR-T cell therapy (REVO-UWD-01) in 30 adults with metastatic colorectal cancer that has spread. The treatment targets a protein called GCC found on cancer cells. The main goals are to find the safest dose and check for side ef…

This study tests a new drug called onvansertib added to standard chemotherapy and a targeted therapy for people with advanced colorectal cancer that has a specific gene change (KRAS or NRAS mutation). About 113 people who have not had prior treatment for their metastatic cancer w…

This study tests two experimental drugs, AK112 and AK117, alone or together, in people with metastatic colorectal cancer that cannot be removed by surgery. The goal is to see if these drugs can shrink tumors or slow the disease. About 254 participants will be enrolled, and the st…

This early-phase study tests a new treatment called WD-01, which uses a patient's own immune cells modified to target a protein (GCC) found on colorectal cancer cells. The goal is to see if it is safe and can shrink tumors in people with metastatic colorectal cancer who have not …

This study compares two immunotherapy drugs (nivolumab alone or with ipilimumab) against standard chemotherapy in people with a specific type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see which treatment works better at slowing cancer growth and improving surviva…

This pilot study aimed to see if adjusting the dose of the chemotherapy drug 5-FU based on its level in the blood could improve treatment for metastatic colorectal cancer. It planned to enroll adults with this cancer who had not received prior treatment for advanced disease. The …

This study tests a new immunotherapy drug, HX008, against standard chemotherapy for people with a specific type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see if HX008 can slow cancer growth better than chemo. About 190 adults with this cancer type will be randoml…

This study tests whether adding two targeted drugs (encorafenib and cetuximab) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with a specific genetic type of advanced colorectal cancer (BRAF V600E-mutant, MSI-H/dMMR) that has spread. Ab…

This study tests whether adding a drug called sodium valproate to standard antibody therapy (panitumumab or cetuximab) can help control metastatic colorectal cancer longer. It involves 38 adults with a specific genetic type (RAS wild type) whose cancer has spread and cannot be cu…

This study compares two drug combinations for people with metastatic colorectal cancer who are not healthy enough for intensive chemotherapy. About 856 participants will receive either trifluridine/tipiracil plus bevacizumab or capecitabine plus bevacizumab. The goal is to see wh…

This study tests whether a new drug (MRTX849) combined with cetuximab works better than standard chemotherapy for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. About 461 participants whose cancer worsened after first treatment will be…

This study tests a new drug, anlotinib, combined with chemotherapy as a first treatment for people with a certain type of advanced colorectal cancer that has spread. About 748 participants will receive either anlotinib plus chemo or a standard treatment (bevacizumab plus chemo). …

This study tests whether adding hydroxychloroquine (a malaria drug) to standard chemotherapy can improve treatment for people with advanced colorectal cancer that has spread. The drug targets cancer cells that survive initial treatment. About 155 participants will be screened, an…

This study was designed for people with advanced colorectal cancer that had stopped responding to standard treatments. It aimed to test a new combination of two immunotherapy drugs: AlloStim and an anti-PDL1 checkpoint inhibitor. The goal was to see if this combination could shri…

This phase 2 study tests two experimental immunotherapy drugs, botensilimab alone or combined with balstilimab, against standard chemotherapy options for people with advanced colorectal cancer that has stopped responding to previous treatments. The goal is to see if these drugs c…

This study tests whether giving anti-EGFR drugs (panitumumab or cetuximab) earlier in treatment can help people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 71 participants with left-sided tumors will receive these drugs, and researchers…

This study looks at whether changes in tumor DNA found in the blood (ctDNA) can predict if chemotherapy is working in people with advanced colorectal cancer that no longer responds to standard treatments. About 103 participants will give blood samples and have regular scans to tr…

This study compares two types of catheters used during a mapping step before liver cancer treatment. The goal is to see if a pressure-enabled device delivers more radioactivity directly to tumors than a standard catheter. Twenty adults with liver cancer will each receive both cat…